GB9824310D0 - Activators of soluble guanylate cyclase - Google Patents

Activators of soluble guanylate cyclase

Info

Publication number
GB9824310D0
GB9824310D0 GBGB9824310.8A GB9824310A GB9824310D0 GB 9824310 D0 GB9824310 D0 GB 9824310D0 GB 9824310 A GB9824310 A GB 9824310A GB 9824310 D0 GB9824310 D0 GB 9824310D0
Authority
GB
United Kingdom
Prior art keywords
activators
guanylate cyclase
soluble guanylate
soluble
cyclase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9824310.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London University College
Original Assignee
London University College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London University College filed Critical London University College
Priority to GBGB9824310.8A priority Critical patent/GB9824310D0/en
Publication of GB9824310D0 publication Critical patent/GB9824310D0/en
Application status is Ceased legal-status Critical

Links

GBGB9824310.8A 1998-11-05 1998-11-05 Activators of soluble guanylate cyclase Ceased GB9824310D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9824310.8A GB9824310D0 (en) 1998-11-05 1998-11-05 Activators of soluble guanylate cyclase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9824310.8A GB9824310D0 (en) 1998-11-05 1998-11-05 Activators of soluble guanylate cyclase
AU64816/99A AU6481699A (en) 1998-11-05 1999-11-05 Activators of soluble guanylate cyclase
PCT/GB1999/003663 WO2000027394A1 (en) 1998-11-05 1999-11-05 Activators of soluble guanylate cyclase

Publications (1)

Publication Number Publication Date
GB9824310D0 true GB9824310D0 (en) 1998-12-30

Family

ID=10841930

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9824310.8A Ceased GB9824310D0 (en) 1998-11-05 1998-11-05 Activators of soluble guanylate cyclase

Country Status (3)

Country Link
AU (1) AU6481699A (en)
GB (1) GB9824310D0 (en)
WO (1) WO2000027394A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1237849A1 (en) * 1999-11-05 2002-09-11 University College London Activators of soluble guanylate cyclase
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
JP2005507922A (en) * 2001-09-19 2005-03-24 ファルマシア・コーポレイションPharmacia Corporation Substituted indazole compounds for the treatment of inflammation
DE10149370A1 (en) * 2001-10-06 2003-04-10 Merck Patent Gmbh New 1-(phenyl or pyridinyl)-1H-pyrazole derivatives, are glycine transporter inhibitors useful e.g. for treating schizophrenia, depression, dementia, neurodegenerative diseases or pain
WO2003076408A2 (en) * 2002-03-08 2003-09-18 Abbott Laboratories Indazole derivatives that are activators of soluble guanylate cyclase
DE10216145A1 (en) * 2002-04-12 2003-10-23 Bayer Ag Use of stimulators of soluble guanylate cyclase to produce a medicament for treating glaucoma
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
CA2507074A1 (en) * 2002-12-02 2004-06-17 F. Hoffmann-La Roche Ag Indazole derivatives as crf antagonists
AR050279A1 (en) 2004-08-03 2006-10-11 Wyeth Corp Indazoles useful as modulators of LXR in the preparation of medicaments leg the treatment of cardiovascular diseases and mediated by Th1 and pharmaceutical compositions containing them as active ingredient.
KR101352012B1 (en) * 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. Sigma receptor inhibitors
MX2007002341A (en) 2004-08-27 2007-09-25 Esteve Labor Dr Sigma receptor inhibitors.
EP1634872A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
AU2005308523B2 (en) 2004-11-29 2010-01-07 Warner-Lambert Company Llc Therapeutic pyrazolo[3,4-b] pyridines and indazoles
JP2008545627A (en) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド How to treat nephrolithiasis
MX2008000141A (en) * 2005-06-27 2008-04-07 Exelixis Inc Imidazole based lxr modulators.
DE102005047945A1 (en) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Use of soluble guanylate cyclase activators for the treatment of Raynaud's phenomena
EP1940397A4 (en) * 2005-08-03 2010-01-20 Takeda Pharmaceuticals North A Methods for treating hypertension
EP1829866A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829873A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrrazole derivatives as sigma receptors antagonists
RS54216B1 (en) 2006-03-22 2015-12-31 F. Hoffmann-La Roche Ag. Pyrazoles as 11-beta-hsd-1
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
DE102007026392A1 (en) 2007-06-06 2008-12-11 Bayer Healthcare Ag Solutions for the perfusion and preservation of organs and tissues
EP2197551B1 (en) * 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2009068652A1 (en) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
WO2009071504A1 (en) * 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2009080227A2 (en) * 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
US8461348B2 (en) 2008-04-04 2013-06-11 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
EP2113501A1 (en) 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CA2753434C (en) * 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
NZ603884A (en) 2010-05-27 2014-06-27 Merck Sharp & Dohme Soluble guanylate cyclase activators
CN107021951A (en) * 2010-06-30 2017-08-08 铁木医药有限公司 SGC stimulators
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
RU2016101964A3 (en) * 2010-11-09 2018-11-21
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2716642B1 (en) 2011-05-30 2016-07-20 Astellas Pharma Inc. Imidazopyridine compound
CA2861804A1 (en) * 2011-12-27 2013-07-04 Ironwood Pharmaceuticals, Inc. 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
CN104736535B (en) 2012-08-24 2017-12-19 德州大学系统董事会 For the heterocyclic modulators for the HIF activity for treating disease
EA027244B1 (en) * 2012-09-07 2017-07-31 Бёрингер Ингельхайм Интернациональ Гмбх Alkoxy pyrazoles as soluble guanylate cyclase activators
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
TW201439090A (en) * 2012-11-30 2014-10-16 Astellas Pharma Inc Imidazopyridine compounds
AU2013361127B2 (en) * 2012-12-21 2018-05-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EA031746B1 (en) * 2013-03-15 2019-02-28 Айронвуд Фармасьютикалз, Инк. STIMULANTS sGC
US20160311826A1 (en) * 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2015091508A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
WO2015130790A2 (en) 2014-02-25 2015-09-03 Board Of Regents, University Of Texas System Salts of heterocyclic modulators of hif activity for treatment of disease
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP2017528494A (en) 2014-09-17 2017-09-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC stimulant
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
WO2017106175A2 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
ES2625037B1 (en) * 2015-12-18 2018-05-11 Consejo Superior De Investigaciones Científicas (Csic) New family of carbony derivatives of 1-indazolil cannabinoid and / or colinergical and / or regulators of the beta-amyloid peptide
WO2018009609A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Solid forms of an sgc stimulator
EA201990238A1 (en) 2016-07-07 2019-07-31 Сайклерион Терапьютикс, Инк. Phosphorus-containing stimulants of sGC stimulants
MX2019002313A (en) 2016-09-02 2019-07-08 Cyclerion Therapeutics Inc Fused bicyclic sgc stimulators.
KR20190094167A (en) 2016-11-08 2019-08-12 사이클리온 테라퓨틱스, 인크. Treatment of CNS Disease with sGC Stimulants
CA3042713A1 (en) 2016-11-08 2018-05-17 Cyclerion Therapeutics, Inc. Sgc stimulators
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2019126354A1 (en) 2017-12-19 2019-06-27 Cyclerion Therapeutics, Inc. Sgc stimulators
WO2019173551A1 (en) 2018-03-07 2019-09-12 Cyclerion Therapeutics, Inc. Crystalline forms of an sgc stimulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS497279A (en) * 1972-05-27 1974-01-22
FR2301250B1 (en) * 1975-02-21 1979-06-29 Bellon Labor Sa Roger
JPH0559892B2 (en) * 1984-11-28 1993-09-01 Kureha Chemical Ind Co Ltd
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
ES2325045T3 (en) * 1996-10-14 2009-08-24 Bayer Healthcare Ag New derivatives of pirazol heterociclilmetil substituted and its use in the treatment of cardiovascular diseases.
DE19649460A1 (en) * 1996-11-26 1998-05-28 Bayer Ag New substituted pyrazole
EP0998274B1 (en) * 1997-06-23 2006-01-18 Cellegy Pharmaceuticals, Inc Microdose therapy of vascular conditions by no donors

Also Published As

Publication number Publication date
AU6481699A (en) 2000-05-29
WO2000027394A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
GB2319250B (en) Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
EG23729A (en) N-alkanoylphenylalanine derivatives
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
GB2342193B (en) Addition circuitry
EP1315513A4 (en) "pseudo"-native chemical ligation
SG85628A1 (en) Compound and its use
AP9801356A0 (en) Prostaglandin agonists
IL142759A (en) Analogues of vitamin d
PL341372A1 (en) Cellecoxibe containing compositions
IL121752D0 (en) Stitching tool
HRP20010454B1 (en) 1,2-annelated quinoline derivatives
PL195240B1 (en) Substituted 3-heterocyclyl-benzoyl derivatives
GB9726810D0 (en) Compounds composition & use
CZ20011556A3 (en) Pyrazolopyridine derivatives
EP0977751A4 (en) Somatostatin agonists
PL334708A1 (en) Readucing union piece
IL140402D0 (en) Antiparasitic artemisinin derivatives (endoperoxides)
HRP980062A2 (en) N-hydroxy-beta-sulfonyl-propionamide derivatives
GB9702194D0 (en) Sulphonide derivatives
IL132033D0 (en) Nicotinamide derivatives
EP0984779A4 (en) Somatostatin agonists
HU0103349A3 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
PL343116A1 (en) Modified starch coating
GB9806789D0 (en) Composition
HU9903072A3 (en) 5,7-dihydroxy-chroman-4-on derivatives as immuno suppressive agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)